Assessment of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker on the split renal function in the patients with primary hypertension

被引:1
|
作者
Zhang, Jingsi [1 ]
Wang, Mingyu [1 ]
Sun, Kehui [1 ]
Ding, Yanchun [1 ]
机构
[1] Dalian Med Univ, Hosp 2, Dept Cardiol 2, Dalian, Peoples R China
关键词
ACEI; ARB; primary hypertension; renal dynamic imaging; split renal function; KIDNEY-DISEASE; BLOOD-PRESSURE; IRBESARTAN; MORTALITY;
D O I
10.1097/MD.0000000000025928
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Bilateral kidney damage in hypertensive patients is not parallel. Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB), as a commonly used antihypertensive drug, could protect kidney function and delay its deterioration. Most studies focused on overall renal function, but the researches on split renal function (SRF) are rare. We investigated the effects of ACEI/ARB on the SRF in patients with primary hypertension. Patients with primary hypertension (n = 429; male: 213; female: 216) admitted to our department between January 2014 and December 2016 were included in this study. The glomerular filtration rate (GFR) of split and total renal function were determined using diethylenetriaminepentaacetic acid tagged with 99mTc renal dynamic imaging method. For the same patient, the side with high GFR was considered as higher GFR kidney, whereas that with a low GFR was considered as lower GFR kidney. The split function score (Q value) was utilized to evaluate the differences of bilateral renal function. The patients were divided into 3 groups based on the Q values (Group 1, Q value <5%; Group 2, Q value of 5%-10%; Group 3, Q value >= 10%). All the patients received antihypertensive therapy based on ACEI/ARB. The renal dynamic imaging was performed in the 1-year follow-up to investigate the changes of the SRF. Compared with the baseline level, significant decline was noticed in the serum creatinine (Scr) in Group 2 and Group 3 (P < .05). The cystatin C in Group 3 showed significant decline (P < .05). Compared with the baseline, there was significant decline in the Q value in Group 2, whereas the GFR of lower GFR kidney showed significant increase (P < .05). No statistical differences were noticed in the Q value and split GFR in Group 1 and Group 3 (P > .05). In primary hypertension patients, ACEI/ARB therapy could improve the SRF of lower GFR kidney in the presence of certain differences between the SRF. As a result, the SRF difference was reduced. In case of Q value in a range of 5% to 10%, ACEI/ARB could improve the renal function effectively. It may be significant for the design of antihypertensive drugs.
引用
收藏
页数:5
相关论文
共 50 条
  • [31] Diabetes and CVD risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment in hypertension: a study of 15 990 patients
    L P Hasvold
    J Bodegård
    M Thuresson
    J Stålhammar
    N Hammar
    J Sundström
    D Russell
    S E Kjeldsen
    Journal of Human Hypertension, 2014, 28 : 663 - 669
  • [32] Clinical evidence from ONTARGET: the value of an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor
    Sleight, Peter
    JOURNAL OF HYPERTENSION, 2009, 27 : S23 - S29
  • [33] Is Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Combination Therapy Better Than Monotherapy and Safe in Patients With CKD?
    Berns, Jeffrey S.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2009, 53 (02) : 192 - 196
  • [34] Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use Among Hypertensive US Adults With Albuminuria
    Chu, Chi D.
    Powe, Neil R.
    McCulloch, Charles E.
    Banerjee, Tanushree
    Crews, Deidra C.
    Saran, Rajiv
    Bragg-Gresham, Jennifer
    Morgenstern, Hal
    Pavkov, Meda E.
    Saydah, Sharon H.
    Tuot, Delphine S.
    HYPERTENSION, 2021, 77 (01) : 94 - 102
  • [35] Therapeutic perspective: starting an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in a diabetic patient
    Jarred, Ghassan
    Kennedy, R. Lee
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2010, 1 (01) : 23 - 28
  • [36] Can an Angiotensin Receptor Blocker Be Used in a Patient in Whom Angioedema Developed With an Angiotensin-Converting Enzyme Inhibitor?
    Cohen, Debbie L.
    Townsend, Raymond R.
    JOURNAL OF CLINICAL HYPERTENSION, 2008, 10 (12): : 949 - 950
  • [37] Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril
    G Bönner
    G L Bakris
    D Sica
    M A Weber
    W B White
    A Perez
    C Cao
    A Handley
    S Kupfer
    Journal of Human Hypertension, 2013, 27 : 479 - 486
  • [38] Smoking and Angiotensin-converting Enzyme Inhibitor/Angiotensin Receptor Blocker Cessation to Limit Coronavirus Disease 2019
    Rossato, Marco
    Di Vincenzo, Angelo
    EUROPEAN CARDIOLOGY REVIEW, 2020, 15
  • [39] Polymorphism of angiotensin-converting enzyme in patients with primary glomerulonephritis and hypertension
    Kuzmanic, D
    Jelakovic, B
    Roncevic, T
    Borso, G
    Sertic, J
    Cvoriscec, D
    Laganovic, M
    Uhl, Z
    Vdovic, M
    JOURNAL OF HYPERTENSION, 1998, 16 : S53 - S53
  • [40] ALDOSTERONE BREAKTHROUGH DURING COMBINED ANGIOTENSIN-CONVERTING ENZYME INHIBITOR AND ANGIOTENSIN II RECEPTOR BLOCKER IN PATIENTS WITH IGA NEPHROPATHY
    Horita, Yoshio
    Tadokoro, Masato
    Taura, Kouichi
    Taguchi, Takashi
    Miyazaki, Masanobu
    Kohno, Shigeru
    NEPHROLOGY, 2005, 10 : A37 - A37